Advanced Glycation End Products Upregulates The Expression Of Connexin43 Via Erk Mapk And Pi3k/Akt Pathways In Human Endothelial Cells

Yanbo Zhao,Lili Wu,Chongying Jin,Jun Lin,Xukun Bi,Zhida Shen,Lu Yu,Guosheng Fu,Junhui Zhu
2019-01-01
Abstract:Intercellular communication through gap junctions plays an essential role in maintaining the functional integrity of vascular endothelium. Despite some emerging evidences suggesting that advanced glycation end products (AGEs) may impair endothelial function, however, its effect on connexin43 (Cx43) gap junction in endothelial cells remains unexplored. Here we investigated the effect of AGE-bovine serum albumin (AGE-BSA) on Cx43 gap junction in endothelial cells. The levels of Cx43 protein in human umbilical vein endothelial cells (HUVECs) was significantly increased by AGE-BSA treatment, accompanied by receptor for advanced glycation endproducts (RAGE) overexpression. This augmentation can be reversed by RAGE knockdown. In addition, AGE-BSA treatment activated the expression of ERK, P38, and JNK mitogen-activated protein kinases (MAPKs), which are supposed to participate in the regulation of Cx43. A MEK inhibitor PD98059, but not SB203580 (a p38 kinase inhibitor) or SP600125 (a JNK kinase inhibitor), abolished the effects of AGE-BSA on Cx43 expression. Moreover, both Akt and PKC phosphorylation were time-dependently augmented by AGE-BSA and PI3K inhibitor LY294002 (but not GF109203X, a PKC inhibitor) blocked the effects of AGE-BSA on Cx43 gap junctions. Taken together, AGE-BSA upregulated Cx43 expression via AGE-RAGE signaling, ERK MAPK and PI3K/Akt Signal transduction pathways appear to be involved in these processes.
What problem does this paper attempt to address?